Velcade (bortezomib) for Injection has been approved by the FDA for use in patients with previously untreated multiple myeloma.
“This comes as wonderful news for patients,” Paul Richardson, MD, Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and a lead investigator for the study related to the approval, said in a news release.
That study, called VISTA—Velcade as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone—produced a 30% complete remission rate with bortezomib compared with 4% for the control arm. “Importantly, patients treated with bortezomib also experienced a survival benefit,” Dr. Richardson added.
© 2008 Lippincott Williams & Wilkins, Inc.